Tariffs should not dictate how Indian drugmakers do business, Cipla CEO says - Reuters.com
3 weeks ago • Google News
Cipla Limited (CIPLA)
NSEINR 1461.90.52%
Price Chart
Key Statistics
Market Cap
INR 1.18T
P/E Ratio
23.65
Revenue (TTM)
INR 267.2B
Volume
804.03K
52W High
INR 1702.05
52W Low
INR 1306.16
Dividend Yield
0.89%
Beta
0.29
Technicals
50-Day MA
1451.97
200-Day MA
1522.5005
52 Week High
1702.05
52 Week Low
1306.1591
About CIPLA
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally.
Employees
27764
Headquarters
Mumbai, India
CEO
Mr. Umang Vohra B.E., M.B.A.
Latest News
Cipla Q3 Results 2025 - Find Cipla Q3 Earnings Result | CIPLA Q3 results - Mint
2 days ago • Google News
Cipla shares in focus after U.S. FDA nod for Leukemia drug - The Economic Times
4 weeks ago • Google News
Environment, Social and Governance (ESG) Risk Ratings
Total ESG Risk Score
37.96
81.38
Environmental Risk Score
4.6
3
Social Risk Score
22.76
3
Governance Risk Score
15.61
3
Controversy Level
ESG data provided by Sustainalytics, Inc.
CIPLA
Category Average
2Moderate Controversy Level
NoneSevere
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg